Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer

被引:13
|
作者
Xiang, Chan [1 ,2 ,3 ]
Gao, Haidong [4 ]
Meng, Lei [5 ]
Qin, Zhaoyu [1 ,2 ,3 ]
Ma, Rong [4 ]
Liu, Yang [1 ,2 ,3 ]
Jiang, Yan [1 ,2 ,3 ]
Dang, Chengxue [5 ]
Jin, Li [1 ,2 ,3 ]
He, Fuchu [1 ,2 ,3 ,6 ]
Wang, Haijian [1 ,2 ,3 ]
机构
[1] Fudan Univ, State Key Lab Genet Engn, Shanghai 200433, Peoples R China
[2] Fudan Univ, Minist Educ, Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 200433, Peoples R China
[3] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250100, Peoples R China
[5] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Surg Oncol, Xian 710049, Peoples R China
[6] Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
TUMOR-TRANSFORMING GENE; BINDING-FACTOR; POPULATION; CHINESE; POLYMORPHISMS; VARIANTS; ALPHA; CYP19;
D O I
10.1111/j.1349-7006.2012.02266.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic polymorphisms in the signalling pathway of estrogen receptor (ER) could modify the risk of breast cancer. A variable number of tandem repeats (VNTR) polymorphism in the promoter of PTTG1IP, pituitary tumor transforming gene binding factor targeted by estrogen receptor a (ERa) in endocrine neoplasia, has been shown to be functional, but its relevance to cancer etiology was unknown. We investigated its association with breast cancer risk by genotyping in 658 patients and 866 controls and further analysed its differential interaction with ERa. We found nine types of alleles ranging from 2 to 9 and 11 repeats that form 29 distinct genotypes and 11 different biallelic repeat numbers. Subjects who carry the six-repeats allele (odds ratio [OR], 1.45; 95% confidence interval [CI], 1.171.79), long alleles (=6 repeats) (OR, 1.55; 95% CI, 1.172.05) or a high dose of biallelic repeats (OR, 1.38; 95% CI, 1.071.77) were at significantly increased risk of cancer. In stratification analysis, these associations consistently manifested in ER-positive breast cancer: in ER positive, PR-positive subtype, genotypes with the six-repeats allele (OR, 1.42; 95% CI, 1.061.90), long alleles (OR, 1.77; 95% CI, 1.172.67) or a high dose of biallelic repeats (OR, 1.67; 95% CI, 1.192.33) were associated with cancer risk; in ER positive, HER2-negative subtype, they were susceptible factors with the ORs being 1.46 (95% CI, 1.062.02), 2.06 (95% CI, 1.283.32) and 1.85 (95% CI, 1.262.71), respectively. Furthermore, functional analysis revealed that an increase in the number of tandem repeats enhances the binding affinity of ERa. The present study provides the first epidemiological evidence that functional regulatory variants of PTTG1IP were associated with the risk of ER-positive breast cancer, further supporting its relevance as one proto-oncogene in breast cancer. (Cancer Sci 2012; 103: 11211128)
引用
收藏
页码:1121 / 1128
页数:8
相关论文
共 48 条
  • [1] Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF
    Imruetaicharoenchoke, W.
    Fletcher, A.
    Lu, W.
    Watkins, R. J.
    Modasia, B.
    Poole, V. L.
    Nieto, H. R.
    Thompson, R. J.
    Boelaert, K.
    Read, M. L.
    Smith, V. E.
    McCabe, C. J.
    ENDOCRINE-RELATED CANCER, 2017, 24 (09) : 459 - 474
  • [2] The HRAS1 variable number of tandem repeats and risk of breast cancer
    Tamimi, RM
    Hankinson, SE
    Ding, SF
    Gagalang, V
    Larson, GP
    Spiegelman, D
    Colditz, GA
    Krontiris, TG
    Hunter, DJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (12) : 1528 - 1530
  • [3] Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer
    Frank, B
    Hemminki, K
    Wappenschmidt, B
    Klaes, R
    Meindl, A
    Schmutzler, RK
    Bugert, P
    Untch, M
    Bartram, CR
    Burwinkel, B
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (11) : 2917 - 2918
  • [4] Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
    Lei, Jonathan T.
    Shao, Jieya
    Zhang, Jin
    Iglesia, Michael
    Chan, Doug W.
    Cao, Jin
    Anurag, Meenakshi
    Singh, Purba
    He, Xiaping
    Kosaka, Yoshimasa
    Matsunuma, Ryoichi
    Crowder, Robert
    Hoog, Jeremy
    Phommaly, Chanpheng
    Goncalves, Rodrigo
    Ramalho, Susana
    Rodrigues Peres, Raquel Mary
    Punturi, Nindo
    Schmidt, Cheryl
    Bartram, Alex
    Jou, Eric
    Devarakonda, Vaishnavi
    Holloway, Kimberly R.
    Lai, W. Victoria
    Hampton, Oliver
    Rogers, Anna
    Tobias, Ethan
    Parikh, Poojan A.
    Davies, Sherri R.
    Li, Shunqiang
    Ma, Cynthia X.
    Suman, Vera J.
    Hunt, Kelly K.
    Watson, Mark A.
    Hoadley, Katherine A.
    Thompson, E. Aubrey
    Chen, Xi
    Kavuri, Shyam M.
    Creighton, Chad J.
    Maher, Christopher A.
    Perou, Charles M.
    Haricharan, Svasti
    Ellis, Matthew J.
    CELL REPORTS, 2018, 24 (06): : 1434 - +
  • [5] Caveolin-1 mutations are associated with relapse in estrogen receptor-positive breast cancer and sensitivity to estrogen.
    Li, T.
    Sparano, J. A.
    Sotgia, F.
    Vuolo, M. A.
    Li, M.
    Yang, W.
    Negassa, A.
    Lisanti, M. P.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S36 - S36
  • [6] Differences of Variable number Tandem repeats in XRCC5 Promoter are associated with increased or Decreased risk of Breast cancer in BRCA gene Mutation carriers
    Cui, Jian
    Luo, Jiangtao
    Kim, Yeong C.
    Snyder, Carrie
    Becirovic, Dina
    Downs, Bradley
    Lynch, Henry
    Wang, San Ming
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [7] Peroxiredoxin-1 Protects Against Oncogene-induced Suppression of the Estrogen Receptor and is a Biomarker of Favourable Prognosis in Estrogen Receptor-positive Breast Cancer
    O'Leary, P. C.
    Brennan, D. J.
    O'Connor, D. P.
    Hennessy, B. T.
    Gonzalez-Angulo, A. M.
    Mills, G. B.
    Jirstrom, K.
    Ponten, F.
    Gallagher, W. M.
    Zagozdzon, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S182 - S182
  • [8] Methylation of the Claudin 1 Promoter Is Associated with Loss of Expression in Estrogen Receptor Positive Breast Cancer
    Di Cello, Francescopaolo
    Cope, Leslie
    Li, Huili
    Jeschke, Jana
    Wang, Wei
    Baylin, Stephen B.
    Zahnow, Cynthia A.
    PLOS ONE, 2013, 8 (07):
  • [9] CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
    Kimbung, Siker
    Inasu, Maria
    Stalhammar, Tor
    Nodin, Bjorn
    Elebro, Karin
    Tryggvadottir, Helga
    Ygland Rodstrom, Maria
    Jirstrom, Karin
    Isaksson, Karolin
    Jernstrom, Helena
    Borgquist, Signe
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [10] CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
    Siker Kimbung
    Maria Inasu
    Tor Stålhammar
    Björn Nodin
    Karin Elebro
    Helga Tryggvadottir
    Maria Ygland Rödström
    Karin Jirström
    Karolin Isaksson
    Helena Jernström
    Signe Borgquist
    Breast Cancer Research, 22